Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
| Autor: | Jaroslava Voglová, Daniela Zackova, Lukas Stejskal, Petra Belohlavkova, Dana Srbova, Lukáš Semerád, Jiri Mayer, Tereza Nečasová, Jirina Prochazkova, Petra Čičátková, Hana Klamova, Zuzana Šustková, Tomas Hornak, Jana Baranova, Barbora Weinbergerova |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Dasatinib Imatinib resistant 03 medical and health sciences 0302 clinical medicine Second line Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine medicine Humans Protein Kinase Inhibitors Retrospective Studies business.industry Imatinib Hematology Long term results Chronic phase chronic myeloid leukemia 3. Good health Clinical Practice Treatment Outcome 030220 oncology & carcinogenesis Leukemia Myeloid Chronic-Phase Imatinib Mesylate business 030215 immunology medicine.drug |
| Zdroj: | Leukemia & Lymphoma. 62:194-202 |
| ISSN: | 1029-2403 1042-8194 |
| DOI: | 10.1080/10428194.2020.1827242 |
| Popis: | To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|